// App-Quantinova.ai

522.0 : HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial.

Researchers

Presenter

  • John Bartlett

Principal Investigators

  • Dennis C. Sgroi

  • Kai Treuner

  • Yi Zhang

  • Tammy Piper

  • Ranelle C. Salunga

  • Ikhlaaq Ahmed

  • Lucy Doos

  • Sarah Thornber

  • Karen J. Taylor

  • Elena F. Brachtel

  • Sarah Pirrie

  • Catherine A. Schnabel

  • Daniel William Rea

Medical Centers

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Center for Cancer Research, Massachusetts General Hospital, Boston, MA

  • bioTheranostics, San Diego, CA

  • University of Birmingham, Birmingham, United Kingdom

  • University of Birmingham, Birmingham, United Kingdom

  • Massachusetts General Hospital, Boston, MA

  • School of Cancer Sciences, Birmingham, United Kingdom

  • University of Birmingham, Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Tamoxifen

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00003678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved